EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients

Sunwen Chou, Sophie Alain iD, Carlos Cervera, Roy F Chemaly, Camille N Kotton, Jens Lundgren iD, Genovefa A Papanicolaou, Marcus R Pereira, Jingyang J Wu, Rose Ann Murray, Neil E Buss, Martha Fournier

The Journal of Infectious Diseases · 2024

DOI: 10.1093/infdis/jiad293 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift The Journal of Infectious Diseases, 2024. Verfasst von Sunwen Chou und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Oregon Health and Science University, Portland, Oregon, USA. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Dichlororibofuranosylbenzimidazole, Ribonucleosides. Die Arbeit wurde bisher 85-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIAID NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This drug resistance analysis of a randomized trial includes 234 patients receiving maribavir and 116 receiving investigator-assigned standard therapy (IAT), where 56% and 24%, respectively, cleared cytomegalovirus DNA at week 8 (treatment responders).

Methods

Baseline and posttreatment plasma samples were tested for mutations conferring drug resistance in viral genes UL97, UL54, and UL27.

Results

At baseline, genotypic testing revealed resistance to ganciclovir, foscarnet, or cidofovir in 56% of patients receiving maribavir and 68% receiving IAT, including 9 newly phenotyped mutations. Among them, 63% (maribavir) and 21% (IAT) were treatment responders. Detected baseline maribavir resistance mutations were UL27 L193F (n = 1) and UL97 F342Y (n = 3). Posttreatment, emergent maribavir resistance mutations were detected in 60 (26%) of those randomized to maribavir, including 49 (48%) of 103 nonresponders and 25 (86%) of the 29 nonresponders where viral DNA initially cleared then rebounded while on maribavir. The most common maribavir resistance mutations were UL97 T409M (n = 34), H411Y (n = 26), and C480F (n = 21), first detected 26 to 130 (median 56) days after starting maribavir.

Conclusions

Baseline maribavir resistance was rare. Drug resistance to standard cytomegalovirus antivirals did not preclude treatment response to maribavir. Rebound in plasma cytomegalovirus DNA while on maribavir strongly suggests emerging drug resistance. Clinical Trials Registration NCT02931539.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytomegalovirus InfectionsDichlororibofuranosylbenzimidazoleRibonucleosidesHumansAntiviral AgentsBenzimidazolesCytomegalovirusDNADrug Resistance, ViralGanciclovirMutationPhosphotransferases (Alcohol Group Acceptor)Transplant Recipients

Stichwörter der Autor:innen

antiviral drug resistanceantiviral therapycytomegalovirusmaribavir

Substanzen

Antiviral AgentsBenzimidazolesDichlororibofuranosylbenzimidazoleDNAGanciclovirmaribavirPhosphotransferases (Alcohol Group Acceptor)Ribonucleosides

Autor:innen und Institutionen

  • Division of Infectious Diseases, Oregon Health and Science University, Portland, Oregon, USA.
  • Research and Development Service, Veterans Affairs Portland Health Care System, Portland, Oregon, USA.
  • Department of Virology and National Reference Center for Herpesviruses, Limoges University Hospital, UMR Inserm 1092, University of Limoges, Limoges, France.
  • Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
  • Department of Infectious Diseases, Infection Control, and Employee Health, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Transplant and Immunocompromised Host Infectious Diseases, Infectious Diseases Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Sophie Alain, Jens Lundgren

Förderung

  • NCI NIH HHS
  • NIAID NIH HHS
  • NIH HHS
  • Takeda Development Center Americas, Inc
  • National Institutes of Health
  • US Department of Veterans Affairs

Zitieren

APA

Chou, S., Alain, S., Cervera, C., Chemaly, R. F., Kotton, C. N., Lundgren, J., Papanicolaou, G. A., Pereira, M. R., Wu, J. J., Murray, R. A., Buss, N. E., & Fournier, M. (2024). Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiad293

Vancouver

Chou S, Alain S, Cervera C, Chemaly RF, Kotton CN, Lundgren J, et al. Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. The Journal of Infectious Diseases. 2024. doi:10.1093/infdis/jiad293

BibTeX
@article{Chou2024,
  author = {Chou, Sunwen and Alain, Sophie and Cervera, Carlos and Chemaly, Roy F and Kotton, Camille N and Lundgren, Jens and Papanicolaou, Genovefa A and Pereira, Marcus R and Wu, Jingyang J and Murray, Rose Ann and Buss, Neil E and Fournier, Martha},
  title = {Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients},
  journal = {The Journal of Infectious Diseases},
  year = {2024},
  doi = {10.1093/infdis/jiad293}
}
Kostenlos starten →